+Compare
EDIT
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
870.23M

EDIT Editas Medicine Forecast, Technical & Fundamental Analysis

a company which translates genome editing technology into a novel class of human therapeutics

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for EDIT with price predictions
07:00 PM EST Nov 27, 2023

Momentum Indicator for EDIT turns positive, indicating new upward trend

EDIT saw its Momentum Indicator move above the 0 level on November 01, 2023. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned positive. In of the 94 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for EDIT just turned positive on October 25, 2023. Looking at past instances where EDIT's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

EDIT moved above its 50-day moving average on November 03, 2023 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for EDIT crossed bullishly above the 50-day moving average on November 10, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in of 268 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 169 cases where EDIT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

EDIT broke above its upper Bollinger Band on November 20, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EDIT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.414) is normal, around the industry mean (20.498). P/E Ratio (0.000) is within average values for comparable stocks, (137.283). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.811). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (31.447) is also within normal values, averaging (329.636).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.29B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 5%. For the same Industry, the average monthly price growth was 37%, and the average quarterly price growth was 8%. AWKNF experienced the highest price growth at 165%, while AXLA experienced the biggest fall at -76%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -16%. For the same stocks of the Industry, the average monthly volume growth was -21% and the average quarterly volume growth was 24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 59
SMR Rating: 94
Profit Risk Rating: 95
Seasonality Score: -6 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

EDIT is expected to report earnings to rise 13.67% to -62 cents per share on February 22

Editas Medicine EDIT Stock Earnings Reports
Q4'23
Est.
$-0.63
Q3'23
Beat
by $0.03
Q2'23
Beat
by $0.21
Q1'23
Est.
$-0.79
Q4'22
Missed
by $0.09
The last earnings report on November 03 showed earnings per share of -55 cents, beating the estimate of -57 cents. With 492.68K shares outstanding, the current market capitalization sits at 870.23M.
A.I. Advisor
published General Information

General Information

a company which translates genome editing technology into a novel class of human therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
11 Hurley Street
Phone
+1 617 401-9000
Employees
226
Web
https://www.editasmedicine.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TCRAX46.300.09
+0.19%
American Century Growth A
NCAVX11.590.01
+0.09%
Nuance Concentrated Value Investor
MEPSX13.05N/A
N/A
MassMutual Disciplined Value R5
ETTGX91.45-0.01
-0.01%
Eaton Vance Tx-Mgd Growth 1.1 A
FGSAX41.79-0.10
-0.24%
Federated Hermes MDT Mid Cap Growth A

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been closely correlated with BEAM. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if EDIT jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
+0.80%
BEAM - EDIT
70%
Closely correlated
+2.09%
NTLA - EDIT
68%
Closely correlated
+0.33%
CRSP - EDIT
65%
Loosely correlated
-1.33%
MDGL - EDIT
61%
Loosely correlated
-3.22%
DNLI - EDIT
60%
Loosely correlated
+2.12%
More

Groups containing EDIT

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
+0.80%
EDIT
(undefined stocks)
80%
Closely correlated
+0.02%
drugs
(undefined stocks)
52%
Loosely correlated
+1.21%
biotechnology
(undefined stocks)
51%
Loosely correlated
+1.26%
human
(undefined stocks)
32%
Poorly correlated
+0.29%
gene-based medicines
(undefined stocks)
25%
Poorly correlated
-0.25%